Business
Satellos Bioscience Inc. to Present Game Changing Science at Insights in Research Investor Summit and MDA Clinical & Scientific Conference 2022
Ryan Mitchell, PhD and Director of Business Development to highlight new advancements with Sat...
About this update from Satellos Bioscience Inc
[{"type":"text","content":"Satellos Bioscience Inc. to Present Game Changing Science at Insights in Research Investor Summit and MDA Clinical & Scientific Conference 2022Ryan Mitchell, PhD and Director of Business Development to highlight new advancements with Satellos' novel muscle regeneration technologyToronto, Ontario--(Newsfile Corp. - March 10, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (\"Satellos\" or the \"Corporation\"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that Satellos has been selected to present at the upcoming Insights in Research Investor Summit and MDA Clinical and Scientific Conference Nashville, Tennessee, March 13-16, 2022. Dr. Ryan Mitchell, Director of Business Development, will make presentations that focus on what Satellos believes to be game changing advancements that the company's researchers are making in the science behind skeletal muscle regeneration. ORAL PRESENTATIONSMarch 13, 2022: 9:10 am - 9:30 am CT (Investor Summit)March 15, 2022: 10:30 am - 10:50 am CT (Clinical Conference)Title: Rebuilding muscle from withinPOSTER PRESENTATIONSMarch 13-15, 2022: 6:00 pm - 8:00 pm CTTitle: Rebuilding muscle in Duchenne by correcting stem cell polarity\"We are excited to share the latest advancements in our efforts to drastically improve the quality of life of individuals with Duchenne, and the unique and proprietary science designed to correct deficits in stem cell polarity that our research has shown are drivers of the progressive muscle destruction of this tragic disease,\" said Frank Gleeson, Satellos Co-Founder and CEO. \"By restoring stem cell polarity and production of muscle progenitor cells via our novel small molecule treatment approach we believe it is possible to restore regeneration thereby modifying disease course and improving outcomes for patients with Duchenne and a range of other dystrophies.\" In his presentation, Dr. Mitchell will present findings that show muscle stem cells in Duchenne are unable to both adequately repair existing and generate new muscle fibers throughout life, which implies that the progressive muscle destruction experienced by people living with Duchenne is actually caused by a failure of the body's natural regeneration process. The presentation will delve into ways we have identifie...